R-X Zhang1, K Ren, R Dubner. 1. Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, MD 21201, USA. rzhan001@umaryland.edu
Abstract
OBJECTIVE: Osteoarthritis (OA) is a complex and painful disease of the whole joint. At present there are no satisfying agents for treating OA. To promote OA research and improved treatment, this review summarizes current preclinical evidence on the development of OA. METHODS: Preclinical OA research was searched and key findings are summarized and commented. RESULTS: Mechanisms of OA-associated pain have been studied in rodent knee OA models produced by intra-knee injection of the chondrocyte glycolytic inhibitor mono-iodoacetate (MIA), surgery, or spontaneous development in some species. These models are clinically relevant in terms of histological damage and functional changes, and are used to study mechanisms underlying mechanical, thermal, ambulatory, body weight supporting-evoked, and ongoing OA pain. Recent peripheral, spinal, and supraspinal biochemical and electrophysiological studies in these models suggest that peripheral pro-inflammatory mediators and neuropeptides sensitize knee nociceptors. Spinal cytokines and neuropeptides promote OA pain, and peripheral and spinal cannabinoids inhibit OA pain respectively through cannabinoid-1 (CB1) and CB1/CB2 receptors. TRPV1 and metalloproteinases contribute and supraspinal descending facilitation of 5-hydroxytryptamine (5-HT)/5-HT 3 receptors may also contribute to OA pain. Conditioned place preference tests demonstrate that OA pain induces aversive behaviors, suggesting the involvement of brain. During OA, brain functional connectivity is enhanced, but at present it is unclear how this change is related to OA pain. CONCLUSION: Animal studies demonstrate that peripheral and central sensitization contributes to OA pain, involving inflammatory cytokines, neuropeptides, and a variety of chemical mediators. Interestingly, brainstem descending facilitation of 5-HT/5-HT3 receptors plays a role OA pain.
OBJECTIVE:Osteoarthritis (OA) is a complex and painful disease of the whole joint. At present there are no satisfying agents for treating OA. To promote OA research and improved treatment, this review summarizes current preclinical evidence on the development of OA. METHODS: Preclinical OA research was searched and key findings are summarized and commented. RESULTS: Mechanisms of OA-associated pain have been studied in rodent knee OA models produced by intra-knee injection of the chondrocyte glycolytic inhibitor mono-iodoacetate (MIA), surgery, or spontaneous development in some species. These models are clinically relevant in terms of histological damage and functional changes, and are used to study mechanisms underlying mechanical, thermal, ambulatory, body weight supporting-evoked, and ongoing OA pain. Recent peripheral, spinal, and supraspinal biochemical and electrophysiological studies in these models suggest that peripheral pro-inflammatory mediators and neuropeptides sensitize knee nociceptors. Spinal cytokines and neuropeptides promote OA pain, and peripheral and spinal cannabinoids inhibit OA pain respectively through cannabinoid-1 (CB1) and CB1/CB2 receptors. TRPV1 and metalloproteinases contribute and supraspinal descending facilitation of 5-hydroxytryptamine (5-HT)/5-HT 3 receptors may also contribute to OA pain. Conditioned place preference tests demonstrate that OA pain induces aversive behaviors, suggesting the involvement of brain. During OA, brain functional connectivity is enhanced, but at present it is unclear how this change is related to OA pain. CONCLUSION: Animal studies demonstrate that peripheral and central sensitization contributes to OA pain, involving inflammatory cytokines, neuropeptides, and a variety of chemical mediators. Interestingly, brainstem descending facilitation of 5-HT/5-HT3 receptors plays a role OA pain.
Authors: Amelia A Mutso; Daniel Radzicki; Marwan N Baliki; Lejian Huang; Ghazal Banisadr; Maria V Centeno; Jelena Radulovic; Marco Martina; Richard J Miller; A Vania Apkarian Journal: J Neurosci Date: 2012-04-25 Impact factor: 6.167
Authors: Katharine L Chu; Prasant Chandran; Shailen K Joshi; Michael F Jarvis; Philip R Kym; Steve McGaraughty Journal: Brain Res Date: 2010-11-01 Impact factor: 3.252
Authors: Vijaykumar M Baragi; Gabriel Becher; Alison M Bendele; Ralf Biesinger; Harald Bluhm; Jürgen Boer; Hongbo Deng; Rory Dodd; Michael Essers; Tim Feuerstein; Brian M Gallagher; Christian Gege; Matthias Hochgürtel; Michael Hofmann; Andreas Jaworski; Lixia Jin; Andrew Kiely; Brian Korniski; Heiko Kroth; Darrell Nix; Bert Nolte; Dorothea Piecha; Timothy S Powers; Frank Richter; Matthias Schneider; Christoph Steeneck; Irving Sucholeiki; Arthur Taveras; Andreas Timmermann; Joshua Van Veldhuizen; Juergen Weik; Xinyuan Wu; Bing Xia Journal: Arthritis Rheum Date: 2009-07
Authors: Chang Z Zhu; Chih-Liang Chin; Nathan R Rustay; Chengmin Zhong; Joe Mikusa; Prasant Chandran; Anita Salyers; Erica Gomez; Gricelda Simler; La Geisha Lewis; Donna Gauvin; Scott Baker; Madhavi Pai; Ann Tovcimak; Jordan Brown; Victoria Komater; Gerard B Fox; Michael W Decker; Peer B Jacobson; Murali Gopalakrishnan; Chih-Hung Lee; Prisca Honore Journal: Biochem Pharmacol Date: 2011-05-17 Impact factor: 5.858
Authors: Warren N D'Souza; Gordon Y Ng; Bradley D Youngblood; Wayne Tsuji; Sonya G Lehto Journal: Curr Pharm Biotechnol Date: 2011-10 Impact factor: 2.837
Authors: Mireia Carcolé; Sami Kummer; Leonor Gonçalves; Daniel Zamanillo; Manuel Merlos; Anthony H Dickenson; Begoña Fernández-Pastor; David Cabañero; Rafael Maldonado Journal: Br J Pharmacol Date: 2019-09-12 Impact factor: 8.739
Authors: Kristofer K Rau; Caitlin E Hill; Benjamin J Harrison; Gayathri Venkat; Heidi M Koenig; Sarah B Cook; Alexander G Rabchevsky; Bradley K Taylor; Tsonwin Hai; Jeffrey C Petruska Journal: Exp Neurol Date: 2016-06-03 Impact factor: 5.330